Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
Montreal, Quebec, H1T2M4, Canada
NCT Number: NCT04163848
Assessing the impact of anesthesia practice on global warming and carbon footprint becomes part of the standard of care and is growing concern within the anesthesia community. Global Warming Potential (GWP) is a measure of how much a given mass of greenhouse gas contributes to global warming over a specified time period. Inhaled anesthetics have various GWP20: 349 for sevoflurane and 3714 for desflurane. However, GWP20 and CDE20 alone are not sufficient to evaluate the environmental impact of anesthetic gases. Other parameters must be included in the analysis: fresh gas flow (FGF), carrier gas (air, O2, N2O) and potency of the anesthetic gas. Unfortunately, the majority of trials did not fully consider the FGF reduction and the fact that desflurane can be administered with new closed or very low-flow anesthesia circuits as opposed as the recommended 2L/min that must be used for sevoflurane according to its monography in Canada. Most of the calculations were made on a purely theoretical approach that could be different from actual measurements based on a strictly monitored anesthesia practice. When continuous and accurate gas monitoring and analysis is used as recommended nowadays, the use of closed or semi-closed-circuit anesthesia with very low FGF might allow for a reduction of more than 80% of the anesthetic gas administration and its consequent pollution. By properly monitoring the anesthesia depth and analgesia adequacy, the investigators can reduce the gas consumption. The proposed study will aim at determining whether with the help of high-quality monitoring (BIS and NOL) and high-end ventilators that allow minimal fresh gas flow, the use of desflurane remains more polluting than sevoflurane.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Montreal, Quebec, H1T2M4, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
Time frame: From intubation to end of surgery
To compare total volatile inhaled anesthetics consumption in CO2 equivalent (grams) per hour during anesthesia for laparoscopic surgery between two groups: Group "D" for Desflurane and group "S" for Sevoflurane
Time frame: From intubation to end of surgery
To compare the total volatile inhaled anesthetics consumption in mL, mL/h and mL/kg/h during anesthesia for laparoscopic surgery between desflurane and sevoflurane
Time frame: From intubation to end of surgery
To compare the total cost of volatile inhalated anesthesics (mL of gaz x $/mL of gaz) for each group
Time frame: From stopping anesthesics gases to extubation
To compare the extubation time
Time frame: From end of surgery to 240minutes post-surgery
To compare the time spent in the recovery room
Ciusss de L'Est de l'Île de Montréal
Other
CARbon Impact of aNesthesic Gas - A Carbon Footprint Comparison of Sevoflurane and Desflurane in an Optimized Fresh Gas Flow Protocol
Acronym: CARING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07178236
Anesthesia, Capnography
Stockholm, Sweden
View Trial DetailsNCT06320743
Anesthesia, Brain Diseases
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT06393998
Acute Mountain Sickness, Altitude Sickness
Guangzhou, Guangdong, China
View Trial DetailsNCT06209112
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Muscat, Mucsat, Oman
View Trial Details